Coding Molecular Determinants of Thyroid Cancer Development and Progression

• Autores: Veronica Valvo, Carmelo Nucera
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 48, Nº. 1, 2019, págs. 37-59
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Thyroid cancer is the most common endocrine malignancy. Its incidence and mortality rates have increased for patients with advanced-stage papillary thyroid cancer. The characterization of the molecular pathways essential in thyroid cancer initiation and progression has made huge progress, underlining the role of intracellular signaling to promote clonal evolution, dedifferentiation, metastasis, and drug resistance. The discovery of genetic alterations that include mutations (BRAF, hTERT), translocations, deletions (eg, 9p), and copy-number gain (eg, 1q) has provided new biological insights with clinical applications. Understanding how molecular pathways interplay is one of the key strategies to develop new therapeutic treatments and improve prognosis.